TScan Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Day: September 22, 2022
Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas
Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support...
Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand
Industry leading nerve repair surgeons will discuss data-driven best practices during symposium sessionALACHUA and TAMPA, Fla., Sept. 22, 2022 (GLOBE...
Tilray Medical Receives Approval to Extend Market Authorization in Italy
Italian Ministry of Health Approves Tilray Branded Medical Cannabis for Pharmaceutical DistributionLEAMINGTON, Ontario and CANTANHEDE, Portugal, Sept. 22, 2022 (GLOBE...
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for...
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim...
More people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with once-daily insulin degludec
Data presented today show more participants achieved greater treatment satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trial...
Inventiva reports its 2022 first-half financial results and provides a corporate update
Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt...
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero...
Spexis announces positive renal impairment clinical trial results with balixafortide
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support...